GLP-1, or glucagon-like peptide-1, is a short hormone made up of 30 or 31 amino acids that the gut releases after meals, primarily to help regulate blood sugar. But that description undersells it. GLP-1 touches the pancreas, brain, stomach, heart, kidneys, fat tissue, and immune system, and its rapid destruction by the body’s own enzymes is one of the reasons it took decades of pharmaceutical ingenuity to turn it into the blockbuster drug class it is today.
From Proglucagon to Active Hormone
GLP-1 does not exist on its own gene. It is carved out of a much larger precursor protein called proglucagon, which also gives rise to glucagon and another peptide called GLP-2. The cutting is done by a specific enzyme, prohormone convertase 1 (PC1), primarily in L-cells lining the lower small intestine and colon. Without PC1, the body cannot process proglucagon into its active fragments. Studies in mice lacking this enzyme found that proglucagon accumulated unprocessed while levels of GLP-1, GLP-2, and related peptides dropped dramatically, confirming that PC1 is the essential tool for producing biologically active GLP-1 in the gut.1Endocrinology. Impaired Intestinal Proglucagon Processing in Mice Lacking Prohormone Convertase 1
The active forms that result from this processing are GLP-1(7–36) amide and GLP-1(7–37), consisting of 30 and 31 amino acids respectively.2Endocrinology and Metabolism. Peptidyl and Non-Peptidyl Oral Glucagon-Like Peptide-1 Receptor Agonists The numbering starts at position 7 rather than 1 because the first six amino acids of the proglucagon-derived GLP-1 sequence are removed during processing; what remains is the biologically active portion. Of the two forms, GLP-1(7–36) amide is the dominant circulating version in humans.
What Triggers Its Release
GLP-1 is secreted when nutrients arrive in the gut. All three major macronutrient types, carbohydrates, fats, and proteins, can trigger secretion, though through different sensing mechanisms. Carbohydrates stimulate L-cells partly through a sodium-glucose transporter (SGLT1) and potassium-ATP channels. Fats work through different molecular sensors, including the free fatty acid receptor FFA1 and a receptor called GPR119.3PubMed Central. The Sensory Mechanisms of Nutrient-Induced GLP-1 Secretion The details of how protein triggers GLP-1 are less well mapped, though amino acids clearly stimulate release as well. What matters for the general picture is that eating a meal, especially one containing a mix of nutrients, is a reliable trigger for GLP-1 to enter circulation.
A Hormone That Barely Lasts
One of GLP-1’s most striking features is how quickly the body destroys it. The enzyme dipeptidyl peptidase IV (DPP-4) clips off the first two amino acids from GLP-1’s active end, turning it into an inactive fragment. This happens so fast that a substantial portion of GLP-1 is already degraded before it even leaves the gut.4PubMed. The physiology of glucagon-like peptide 1 DPP-4 sits on the surface of endothelial, epithelial, and other cell types, making it essentially unavoidable for any GLP-1 molecule traveling through the bloodstream.5PubMed. Mechanisms underlying the rapid degradation and elimination of the incretin hormones GLP-1 and GIP
The result is an intact half-life of roughly one to two minutes. For a hormone with such wide-ranging effects, that brevity initially puzzled researchers. It raised the possibility that GLP-1 does not always need to travel through the bloodstream to act. Instead, some of its effects may be transmitted through sensory nerve endings in the intestine and liver that express GLP-1 receptors, picking up the signal locally before DPP-4 has a chance to destroy it.4PubMed. The physiology of glucagon-like peptide 1 This “paracrine” signaling, where the hormone acts on nearby cells and nerves rather than traveling far through the blood, helps explain how something so short-lived can still have meaningful effects on distant organs like the brain.
How GLP-1 Lowers Blood Sugar
The best-known function of GLP-1 is enhancing insulin secretion from the pancreas. When GLP-1 binds its receptor on beta cells, it amplifies the insulin response that glucose itself triggers. This is a critical nuance: GLP-1 does not force beta cells to release insulin regardless of blood sugar levels. Its effect on insulin secretion is glucose-dependent, meaning it has little or no activity when blood sugar is normal and ramps up when glucose is elevated.6PubMed Central. GLP-1 receptor activated insulin secretion from pancreatic β-cells: mechanism and glucose dependence This built-in safety feature is a major reason why GLP-1-based drugs carry a much lower risk of causing dangerously low blood sugar compared to older diabetes medications like sulfonylureas.
GLP-1 also suppresses glucagon, a hormone released by the pancreas’s alpha cells that raises blood sugar by prompting the liver to release stored glucose. By dialing down glucagon at the same time it dials up insulin, GLP-1 attacks high blood sugar from two directions simultaneously.7PubMed Central. Glucagon-Like Peptide-1 and Hypothalamic Regulation of Satiation: Cognitive and Neural Insights from Human and Animal Studies
Slowing the Stomach
Beyond the pancreas, GLP-1 puts the brakes on gastric emptying, the rate at which food moves from the stomach into the small intestine. Slower emptying means glucose from a meal enters the bloodstream more gradually, flattening the post-meal blood sugar spike. In studies using GLP-1 receptor agonists, gastric half-emptying times for liquids and solids have been increased by up to roughly three-fold compared to placebo, and this slowing can occur at doses lower than those typically used for glucose control in type 2 diabetes.8Endocrinology. Physiology and Pharmacology of Effects of GLP-1-based Therapies on Gastric, Biliary and Intestinal Motility
This gastric-slowing effect also contributes to weight loss in people taking GLP-1-based drugs. When your stomach holds food longer, you tend to eat less at subsequent meals. The effect is integral to both postprandial glucose control and the appetite suppression that has made these drugs famous for weight management.8Endocrinology. Physiology and Pharmacology of Effects of GLP-1-based Therapies on Gastric, Biliary and Intestinal Motility It is also the source of the nausea and gastrointestinal discomfort that many users report, particularly when starting treatment.
GLP-1 in the Brain
GLP-1 receptors are found throughout the central nervous system, including regions of the hypothalamus and brainstem that regulate hunger and fullness. GLP-1 acts on these circuits to promote satiation, the feeling that you have eaten enough, and satiety, the sustained feeling of fullness between meals.7PubMed Central. Glucagon-Like Peptide-1 and Hypothalamic Regulation of Satiation: Cognitive and Neural Insights from Human and Animal Studies This central appetite regulation works alongside the gastric-slowing effect described above to reduce food intake.
But the brain story goes beyond appetite. GLP-1 is also produced locally in the brain, not just in the gut, and accumulating evidence points to neuroprotective roles. In preclinical models of neurodegenerative disease, activation of brain GLP-1 receptors has shown anti-inflammatory properties and appears to support neuron survival and even new neuron growth.9PubMed Central. Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases10PubMed Central. Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders These findings are still largely from cell and animal studies, and how well they translate to human neurological conditions remains under active investigation. But the presence of GLP-1 receptors in the brain and the consistent direction of these early findings are a major reason researchers are testing GLP-1 drugs in conditions like Alzheimer’s and Parkinson’s disease.
Cardiovascular and Kidney Effects
GLP-1 receptors are also expressed in the heart and blood vessels. Activating them stimulates the inner lining of blood vessels to produce nitric oxide, which relaxes vessel walls and helps maintain healthy blood pressure. Research also points to reduced oxidative stress and anti-inflammatory effects within the vascular system.11PubMed Central. The benefits of GLP1 receptors in cardiovascular diseases Across both preclinical and clinical data, GLP-1 receptor agonists show cardiovascular protective effects, particularly for vascular health and a form of heart failure where the heart muscle stiffens rather than weakens.12JCI Insight. GLP-1 and the cardiovascular system
In the kidneys, GLP-1 receptor activation appears to affect how the proximal tubules handle sodium. In patients with type 2 diabetes treated with a GLP-1 receptor agonist, researchers found increased phosphorylation of a sodium transporter (NHE3), suggesting reduced sodium reabsorption in the kidney.13PubMed. Renal tubular effects of prolonged therapy with the GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes mellitus This could contribute to the mild blood pressure reductions seen with these drugs and is part of the broader interest in whether GLP-1-based therapies protect kidney function over time.
Effects on Fat and Liver Tissue
GLP-1 signaling reaches metabolic tissues beyond the pancreas. In animal models, treatment with a GLP-1 receptor agonist reduced both the weight and fat content of liver tissue in obese mice, along with decreased markers of lipid metabolism and lower circulating levels of a ketone body that reflects fat breakdown.14iScience. Recombinant human GLP-1 beinaglutide targets lipid profiles and lipid metabolism of adipose tissues in obese mice These observations fit with clinical findings that GLP-1 drugs tend to improve liver fat in people with metabolic-associated fatty liver disease, though the relative contribution of direct GLP-1 receptor effects versus indirect benefits from weight loss and improved blood sugar is still being sorted out.
Anti-Inflammatory Actions in the Immune System
One of the more recently explored dimensions of GLP-1 biology is its direct interaction with immune cells. GLP-1 receptors are expressed on certain immune cells in the gut lining, including a population of T cells. When GLP-1 activates its receptor on these cells, it dampens early T cell signaling, reducing the production of inflammatory molecules like interferon-gamma and TNF-alpha.15JCI Insight. Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits This anti-inflammatory role in the gut may partly explain why GLP-1-based therapies appear to have benefits in inflammatory conditions beyond diabetes and obesity, though research is still early in defining the scope of these effects.
The Metabolite That Still Does Something
When DPP-4 clips GLP-1(7–36) amide, the resulting fragment is GLP-1(9–36) amide. For years it was considered inert, a waste product. That turns out to be wrong. In a controlled study in humans, infusion of this metabolite reduced postprandial blood sugar by about 6 mg/dL compared to placebo, and it did so without affecting insulin levels, glucagon levels, or gastric emptying.16PubMed. The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans The most likely explanation is a direct effect on how tissues take up and dispose of glucose. This finding suggests that GLP-1’s full biological story is not captured by looking at the intact hormone alone, and that even the “degraded” form carries metabolic signals.
An Ancient Hormone with a Shifting Job
The proglucagon gene is ancient, and GLP-1-like sequences appear across vertebrates from fish to mammals. Glucagon, GLP-1, and GLP-2 are all thought to have arisen from tripplication of an ancestral glucagon-encoding segment.17PubMed. Insights into the evolution of proglucagon-derived peptides and receptors in fish and amphibians But while the gene’s structure has been remarkably conserved, the functions of its products have not stayed the same. In fish, GLP-1 acts more like a second glucagon, raising blood sugar rather than lowering it. The incretin function, enhancing insulin release in response to a meal, appears to be a mammalian innovation.18PubMed. Molecular evolution of proglucagon
Analysis of proglucagon sequences across 168 mammalian species shows that the gene is present as a single copy in nearly all genomes, though some lineages have accumulated interesting variations. Certain bat species, for instance, show changes in the processing sites that may affect how GLP-1 is produced, and rodents like guinea pigs have unusually divergent glucagon sequences.19PubMed Central. Variation in the Evolution and Sequences of Proglucagon and the Receptors for Proglucagon-Derived Peptides in Mammals Researchers interpret these patterns as evidence that proglucagon-derived peptides may have a broader diversity of biological roles across mammals than currently appreciated.
From Gila Monster Venom to the Pharmacy
The story of how GLP-1 became one of the most important drug targets in modern medicine has an unusual origin. In the 1990s, researchers investigating the venom of the Gila monster (Heloderma suspectum) isolated a 39-amino-acid peptide called exendin-4 that shared about 53% of its structure with human GLP-1(7–36).20PubMed. The development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent Exendin-4 activated the GLP-1 receptor just as effectively as GLP-1 itself, but with one enormous practical advantage: it was far more resistant to DPP-4 degradation, giving it a much longer working life in the body.21PubMed. Exendin-4 from Heloderma suspectum venom: From discovery to its latest application as type II diabetes combatant A synthetic version, exenatide, became the first GLP-1 receptor agonist approved for type 2 diabetes in 2005.20PubMed. The development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent
Later-generation drugs like liraglutide and semaglutide took a different approach. Rather than borrowing a lizard peptide, they started with the human GLP-1 sequence and engineered it for longevity. Both drugs use a fatty acid chain that causes them to bind reversibly to albumin, a large protein in the blood. Albumin acts as a slow-release shuttle, shielding the drug from DPP-4 and extending its effective life from minutes to days or even a week.22PubMed Central. The Discovery and Development of Liraglutide and Semaglutide Semaglutide in particular was optimized with specific fatty acid and linker combinations to maximize albumin binding without sacrificing receptor potency, which is why it can be dosed once weekly by injection or once daily as a pill.
Dual Agonists and the Next Wave
The latest evolution in this drug class goes beyond GLP-1 alone. Tirzepatide, approved in 2022, activates both the GLP-1 receptor and the receptor for another gut hormone called GIP (glucose-dependent insulinotropic polypeptide). Combining signals from both receptors produces stronger effects on blood sugar control and weight loss than GLP-1 stimulation alone.23PubMed Central. Tirzepatide: A Novel, Once-weekly Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes24PubMed Central. The Clinical Application of GLP-1RAs and GLP-1/GIP Dual Receptor Agonists Based on Pharmacological Mechanisms: A Review Researchers are also developing triple agonists that add glucagon receptor activation to the mix, aiming to further enhance energy expenditure and metabolic improvement. These newer molecules are built on the foundation of understanding what GLP-1 does in the body, then layering on additional hormonal signals that work through complementary pathways.
This trajectory from a rapidly destroyed gut hormone to a multi-billion-dollar drug class illustrates something genuinely interesting about GLP-1: the sequence itself was never the bottleneck for therapeutic use. The biology was always compelling. The challenge was keeping it alive long enough to matter. Every generation of GLP-1-based therapy, from Gila monster venom mimics to fatty-acid-shielded analogues to multi-receptor agonists, has been a different engineering solution to the same core problem of DPP-4 degradation and rapid clearance.